AGENUS INC
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $34.50M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | $33.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $25.70M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | $24.10M | $-1.03 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | $26.80M | $-2.04 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $25.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | $23.50M | $-2.52 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on May 12, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| annualized operating cash burn | starting in the second half of 2025 | $50.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Agenus filed with the SEC
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Results of operations · EX-99.1 to Form 8-K
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Financing Announcement July 13, 2026
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Results of operations · EX-99.1 to Form 8-K
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Results of operations · EX-99.1 to Form 8-K
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED CONDENSED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION
Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Results of operations · EX-99.1 to Form 8-K
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
Results of operations · EX-99.1 to Form 8-K
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Agenus Reports Q1 2025 Financial Results and Key Business Updates
Results of operations · EX-99.1 to Form 8-K
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
Results of operations · EX-99.1 to Form 8-K
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
Results of operations · EX-99.1 to Form 8-K
Agenus Reports Second Quarter 2024 Operational and Financial Results
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Agenus Announces Appointment of Tom Harrison to Board of Directors
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
Agenus Reports First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Agenus Reports Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Strategic Initiatives Highlighting Our Fundamental Strengths
Regulation FD disclosure · EX-99.1 to Form 8-K
Agenus Reports Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Agenus Reports Second Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
Other events · EX-99.1 to Form 8-K
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
Results of operations · EX-99.1 to Form 8-K
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
Results of operations · EX-99.1 to Form 8-K
Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
Results of operations · EX-99.1 to Form 8-K
Agenus Corporate Update and First Quarter 2022 Financial Report
Results of operations · EX-99.1 to Form 8-K
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
Results of operations · Other events · EX-99.1 to Form 8-K
Agenus Corporate Update and Third Quarter 2021 Financial Report
Results of operations · EX-99.1 to Form 8-K
Agenus Provides Update on Balstilimab Development
Other events · EX-99.1 to Form 8-K